|
|
|
| Application Effect of Recombinant Bovine Basic Fibroblast Growth Factor Eye Drops Combined with Olopatadine Eye Drops in Allergic Conjunctivitis |
| SUN Wei, RONG Fei |
| First-author's address: Suzhou Ninth People's Hospital, Jiangsu Province, Suzhou 215200, China |
|
|
|
|
Abstract Objective: To investigate the application effect of Recombinant Bovine Basic Fibroblast Growth Factor Eye Drops (trade name: Beifushu) combined with Olopatadine Eye Drops in allergic conjunctivitis. Method: A total of one hundred and fifteen patients with allergic conjunctivitis admitted to Suzhou Ninth People's Hospital between July 2019 and June 2022 were selected for this study and divided into control group (n=58) and study group (n=57) by random number table method. The control group was treated with Olopatadine Eye Drops, the study group was treated with Beifushu in combination with Olofadine Eye Drops. The efficacy, inflammatory level, immune level, tear film stability and occurrence of adverse drug reactions were compared between the two groups. Result: The efficacy of the study group was significantly better than that of the control group (P<0.05). Before treatment, there were no significant differences in the levels of eosinophil cationic protein (ECP), hypersensitivity c reactive protein (hs-CRP), and interleukin-10 (IL-10) between the two groups (P>0.05); after treatment, the levels of ECP and hs-CRP in the two groups were significantly decreased compared with those before treatment (P<0.05), the study group were significantly lower than those of the control group (P<0.05); the levels of IL-10 in the two groups increased significantly compared with those before treatment (P<0.05), the study group was significantly higher than that of the control group (P<0.05). Before treatment, there were no statistically significant differences in the levels of immunoglobulin A (IgA) and immunoglobulin E (IgE) between the two groups (P>0.05); after treatment, the levels of IgA and IgE in both groups decreased significantly compared with those before treatment (P<0.05), the study group were significantly higher than those in the control group (P<0.05). Before treatment, there were no statistically significant differences in tear film break up time (BUT), corneal fluorescein staining scores and tear secretion test between the two groups (P>0.05); after treatment, the corneal fluorescein staining scores decreased significantly compared with those before treatment (P<0.05), and tear secretion test significant increase compared with those before treatment (P<0.05), the study group were significantly higher than those in the control group (P<0.05); the levels of BUT in the two groups increased significantly compared with that before treatment (P<0.05), the study group was significantly higher than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combined treatment of Recombinant Bovine Basic Fibroblast Growth Factor Eye Drops and Olofatadine Eye Drops in patients with allergic conjunctivitis has significant effects, significantly improving the levels of inflammation and immunity, and improving the stability of tear film without increasing adverse drug reactions, which is safe and controllable.
|
|
Received: 01 December 2022
|
|
|
|
|
|
|
